Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612320 | 1.00 | CA2 (0.61) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL7515977 | 1.00 | CA2 (0.61) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL8324700 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL9397701 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL8319690 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL5698787 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL10964151 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL22612259 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL13539144 | 0.98 | CA2 (0.57) | CA2MAPK1GRIK1GRIK2GPR84 | |
| SCHEMBL9092793 | 0.95 | CA2 (0.54) | CA2MAPK1GRIK1GRIK2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1285652-B1 | Novel fatty acid analogues for the treatment of hypertension | THIA MEDICA AS (NO) | 2006-08-16 | — | — | EP | disclosed |
| EP-1284139-B1 | Novel fatty acid analogues for the treatment of fatty liver | THIA MEDICA AS (NO) | 2006-08-02 | — | — | EP | disclosed |
| EP-1075260-B1 | NOVEL FATTY ACID ANALOGUES FOR THE TREATMENT OF SECONDARY RESTENOSIS | THIA MEDICA AS (NO) | 2005-10-19 | — | — | EP | disclosed |
| EP-1075258-B1 | NOVEL FATTY ANALOGUES FOR THE TREATMENT OF OBESITY | THIA MEDICA AS (NO) | 2003-08-20 | — | — | EP | disclosed |
| EP-1075259-B1 | NOVEL FATTY ANALOGUES FOR THE TREATMENT OF DIABETES | THIA MEDICA AS (NO) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA2 150/4885MAPK1 2443/4885GRIK1 705/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | CA2 1054/4885MAPK1 4455/4885GRIK1 2238/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | CA2 797/4885MAPK1 4467/4885GRIK1 2042/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CA2 1003/4885MAPK1 4494/4885GRIK1 2533/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | CA2 1003/4885MAPK1 4494/4885GRIK1 2533/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CA2 1003/4885MAPK1 4494/4885GRIK1 2533/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CA2 156/4885MAPK1 2456/4885GRIK1 706/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | CA2 316/4885MAPK1 2752/4885GRIK1 1324/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CA2 156/4885MAPK1 2393/4885GRIK1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.